Vanadium/vanadyl sulfate

Alternative Medicine Review

Volumn 14, Issue 2, 2009, Pages 177-180

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BIS(ETHYLMALTOLATO)OXOVANADIUM; BIS(MALTOLATO)OXOVANADIUM; HEPARIN; INSULIN; ORAL ANTIDIABETIC AGENT; UNCLASSIFIED DRUG; VANADATE SODIUM; VANADIUM; VANADYL SULFATE;

ABDOMINAL CRAMP; CATARACT; CLINICAL TRIAL; DENTAL CARIES; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIET SUPPLEMENTATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; GASTROINTESTINAL SYMPTOM; GLUCONEOGENESIS; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HUMAN; HYPERLIPIDEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN SENSITIVITY; LOOSE FECES; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REVIEW; SYPHILIS;

ANIMALS; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS; DIABETES MELLITUS, EXPERIMENTAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYPOGLYCEMIC AGENTS; VANADIUM COMPOUNDS;

EID: 67650941931     PISSN: 10895159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Cintas P. The road to chemical names and eponyms: discovery, priority, and credit. Angew Chem Int Ed Engl 2004;43:5888-5894. (Pubitemid 39551318)
2. Poucheret P, Verma S, Grynpas MD, McNeill JH. Vanadium and diabetes. Mol Cell Biochem 1998;188:73-80.
3. Sakurai H, Katoh A, Yoshikawa Y. Chemistry and biochemistry of insulin-mimetic vanadium and zinc complexes. Trial for treatment of diabetes mellitus. Bull Chem Soc Jpn 2006;79:1645-1664.
4. Barceloux DG. Vanadium. J Toxicol Clin Toxicol 1999;37:265-278.
5. th ed. Stockton, CA: Therapeutic Research Faculty; 2006:1258-1260.
6. Tracey AS, Willsky GR, Takeuchi ES. Vanadium Chemistry, Biochemistry, Pharmacology and Practical Applications. Boca Raton, FL: CRC Press; 2007:181-185.
7. Hamel FG, Duckworth WC. The relationship between insulin and vanadium metabolism in insulin target tissues. Mol Cell Biochem 1995;153:95-102. (Pubitemid 26003371)
8. Heinemann G, Fichtl B, Vogt W. Pharmacokinetics of vanadium in humans after intravenous administration of a vanadium containing albumin solution. Br J Clin Pharmacol 2003;55:241-245. (Pubitemid 36390753)
9. Verma S, Cam MC, McNeill JH. Nutritional factors that can favorably influence the glucose/insulin system: vanadium. J Am Coll Nutr 1998;17:11-18. (Pubitemid 28081135)
10. Bhattacharyya S, Tracey AS. Vanadium(V) complexes in enzyme systems: aqueous chemistry, inhibition and molecular modeling in inhibitor design. J Inorg Biochem 2001;85:9-13.
11. Shamberger RJ. The insulin-like effects of vanadium. J Adv Med 1996;9:121-131.
12. Nielsen FH. Ultratrace elements in nutrition. Ann Rev Nutr 1984;4:21-41.
13. Jackson DE. The pharmacological actions of vanadium. J Pharmacol 1912;3:477-514.
14. Nielsen FH. Vanadium Compounds: Chemistry, Biochemistry, and Therapeutic Applications, ACS Symp. Ser. 711. Tracey AS, Crans DC, eds. American Chemical Society: Wash DC; 1998.
15. Thompson KH, Lichter J, LeBel C, et al. Vanadium treatment of type 2 diabetes: a view to the future. J Inorg Biochem 2009;103:554-558.
16. Lyonnet B, Martz X, Martin E. Therapeutic use of the derivatives of vanadium La Presse Med 1899;1:191. [Article in French]
17. Boden G, Chen X, Ruiz J, et al. Effects of vanadyl sulfate on carbohydrate and lipid metabolism in patients with non-insulin-dependent diabetes mellitus. Metabolism 1996;45:1130-1135. (Pubitemid 26300313)
18. Cohen N, Halberstam M, Shlimovich P, et al. Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 1995;95:2501-2509.
19. Halberstam M, Cohen N, Shlimovich P, et al. Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects. Diabetes 1996;45:659-666. (Pubitemid 26140551)
20. Goldfine AB, Patti ME, Zuberi L, et al. Metabolic effects of vanadyl sulfate in humans with non-insulin-dependent diabetes mellitus: in vivo and in vitro studies. Metabolism 2000;49:400-410. (Pubitemid 30146574)
21. Bosia S, Burdino E, Grignolo F, Ugazio G. Protective effect on nephropathy and on cataract in the streptozotocin-diabetic rat of the vanadium-lazaroid combination. G Ital Med Lav 1995;17:71-75. [Article in Italian]
22. Brichard SM, Henquin JC. The role of vanadium in the management of diabetes. Trends Pharmacol Sci 1995;16:265-270.
23. Jacques-Camarena O, González-Ortiz M, Martínez-Abundis E, et al. Effect of vanadium on insulin sensitivity in patients with impaired glucose tolerance. Ann Nutr Metab 2008;53:195-198.
24. Funakoshi T, Shimada H, Kojima S, et al. Anticoagulant action of vanadate. Chem Pharm Bull (Tokyo) 1992;40:174-176.
25. Yuen VG, Orvig C, McNeill JH. Comparison of the glucose-lowering properties of vanadyl sulfate and bis(maltolato)oxovanadium(IV) following acute and chronic administration. Can J Physiol Pharmacol 1995;73:55-64.
26. No authors listed. Arsenic, boron, nickel, silicon, and vanadium. In: Food and Nutrition Board, Institute of Medicine, eds. Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. Washington, DC: National Academy Press; 2002:533-543. Available at: www.nap.edu/books/0309072794/html/